Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 14, 2026 at 5:01 AM GMT+3 3 min read

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance and Market Positioning

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Revenue growth was primarily driven by increased Elfabrio sales to Chiesi, reflecting deeper global market penetration and inventory management strategies.
Management attributes the strong first-half performance to the combination of commercial scaling and a $25 million milestone payment recognized in Q1 2026.
The company is strategically focused on the rare renal disease market, leveraging its proprietary platform to maintain a competitive advantage in specialized therapeutic areas.
Profitability is being sustained through a business model designed to limit downside risks while preserving upside through clinical program advancements.
Operational efficiency was bolstered by a $2.1 million reduction in R&D expenses resulting from a new ongoing grant available under the R&D law.
Management views the recent European approval of Elfabrio's once-every-4-weeks dosing regimen as a key strengthener of their partnership with Chiesi.

Clinical Milestones and Market Outlook

Protalix projects the global Fabry market will reach approximately $3.2 billion by 2031, with a target to capture 15% to 20% of this market share.
Top-line results for the RELEASE study evaluating PRX-115 in uncontrolled gout are expected in the second half of 2027.
Management expects to finalize enrollment for the PRX-115 Phase 2 study by the end of 2026, with nearly all clinical sites currently active.
Future revenue is expected to remain 'lumpy' on a quarter-to-quarter basis due to the timing of partner shipments and inventory cycles, necessitating a full-year evaluation approach.
The company maintains a strong cash position of $40.7 million with no outstanding debt, providing the financial flexibility required to fund ongoing clinical and preclinical programs.

Financial and Regulatory Considerations

Taxes on income increased to $1.1 million due to GILTI tax limitations under IRC Section 174.
The company secured a patent term extension for Elfabrio and received new regulatory approval in South Korea, expanding its commercial footprint.
R&D expenses are expected to rise in future periods as the RELEASE study progresses and additional pipeline programs advance.

Q&A Session Insights

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Selection criteria for PRX-115 Phase 3 dosing regimens

Management is evaluating four arms in the Phase 2 RELEASE study, including every-4-weeks without methotrexate and every-8-weeks with methotrexate.
The decision on which regimen advances will depend on the totality of evidence regarding immunogenicity, infusion-related reactions (IRR), and patient convenience.
Eliminating methotrexate or extending dosing frequency are both considered significant potential competitive advantages.

Rationale for PRX-115 36-milligram fixed dose and ADA profiles

The 36-milligram dose was selected based on PK/PD data from Phase 1 and the goal of achieving the most convenient patient dosing schedule.
Phase 2 will provide a clearer picture of anti-drug antibodies (ADAs) against the enzyme across different treatment arms compared to the single ascending dose Phase 1 study.

Impact of competitor price increases in the gout market

Management noted the growth of the uncontrolled gout market, citing Krystexxa's revenue trend toward $1.6 billion as an encouraging sign for PRX-115's potential.
While acknowledging competitor price increases, management focused on the overall market expansion as the primary indicator of the opportunity for their differentiated uricase.